### stryker

### LATERA absorbable nasal implant system

# New real-world evidence shows Payers save ~\$2,200 per patient'

All-cause costs and resource utilization compared to surgical repair of nasal valve collapse (NVC)

**5,032** LATERA

**LATERA** patients 26,553 Surgical repair patients

Subgroup analysis shows \$100 PPPM savings in patients who underwent LATERA concomitantly with septoplasty and IT reduction.



## Total cost on index date:

LATERA: **\$9,612** Compared to surgical repair: **\$11,846** 

## **Benefits of LATERA**

- 8 clinical publications including RCT<sup>2-9</sup> Results demonstrate significant improvement in nasal obstruction symptoms
- 😔 24-month durability<sup>2-4</sup>

### Non-inferior to functional rhinoplasty techniques<sup>o</sup>

LATERA patients experienced an average NOSE score improvement of **40.5** compared to 40.1 for rhinoplasty group

Positive clinical effect on sleep quality<sup>4</sup>

Patients exhibiting daytime sleepiness prior to LATERA demonstrated significant improvement in Epworth Sleepiness Score

### AAO position statement<sup>10</sup>

The nasal valve may be stabilized using office-based treatments, such as implants.

Failure to perform nasal valve repair, when indicated, is a common cause of incomplete symptom resolution for patients with nasal obstruction and nasal valve dysfunction.

Requiring septoplasty and/or turbinate surgery prior to nasal valve surgery is not recommended, as this may lead to unnecessary increases in surgical encounters.

### **ARS** position statement<sup>11</sup>

The American Rhinologic Society (ARS) supports the use of a bioabsorbable nasal implant to treat nasal obstruction. This procedure should not be considered experimental but should be considered as an effective option in treating nasal valve collapse and improving patient quality of life. LATERA

## Treatment of NVC with the LATERA absorbable nasal

**implant** is a cost-saving, minimallyinvasive procedure that supports the cartilage of both the internal and external valve to help increase airflow and reduce symptoms of nasal airway obstruction (NAO).

### New diagnosis codes effective October 1, 2024<sup>12</sup>

Code	Description
J34.8200	Internal nasal valve collapse, unspecified
J34.8201	Internal nasal valve colapse, static
J34.8202	Internal nasal valve collapse, dynamic
J34.8210	External nasal valve collapse, unspecified
J34.8211	External nasal valve collapse, static
J34.8212	External nasal valve collapse, dynamic
J34.829	Nasal valve collapse, unspecified

#### Category I CPT<sup>®</sup> code effective Jan 1, 2021

- 30468: Repair of nasal valve collapse with subcutaneous/ submucosal lateral wall implant(s)
- Reports bilateral NVC treatment

#### **References:**

- 1. Internal Stryker data. ENT-LATSYS-REIM-1031465. Manuscript submitted for publication.
- San Nicoló M, Stelter K, Sadick H, Bas M, Berghaus A. A 2-Year Follow-up Study of an Absorbable Implant to Treat Nasal Valve Collapse. Facial Plast Surg. 2018 Oct;34(5):545-550
- Sidle DM, Stolovitzky P, O'Malley EM, Ow RA, Nachlas NE, Silvers S. Bioabsorbable Implant for Treatment of Nasal Valve Collapse with or without Concomitant Procedures. Facial Plast Surg. 2021 Oct;37(5):673-680.
- 4. Bikhazi N, Ow RA, O'Malley EM, Perkins N, Sidle DM, Stolovitzky P. Long-Term Follow-up from the Treatment and Crossover Arms of a Randomized Controlled Trial of an Absorbable Nasal Implant for Dynamic Nasal Valve Collapse. Facial Plast Surg. 2021;10.1055/s-0041-1740948.
- 5. San Nicoló M, Stelter K, Sadick H, Bas M, Berghaus A. Absorbable Implant to Treat Nasal Valve Collapse. Facial Plast Surg. 2017 Apr;33(2):233-240.
- Sidle DM, Stolovitzky P, Ow RA, Silvers S, Matheny K, Bikhazi N, Wani M, Scurry WC, Most SP. Twelve-month outcomes of a bioabsorbable implant for in-office treatment of dynamic nasal valve collapse. Laryngoscope. 2020 May;130(5):1132-1137.

- Stolovitzky P, Sidle DM, Ow RA, Nachlas NE, Most SP. A prospective study for treatment of nasal valve collapse due to lateral wall insufficiency: Outcomes using a bioabsorbable implant. Laryngoscope. 2018 Nov;128(11):2483-2489.
- Stolovitzky P, Senior B, Ow RA, Mehendale N, Bikhazi N, Sidle DM. Assessment of bioabsorbable implant treatment for nasal valve collapse compared to a sham group: a randomized control trial. Int Forum Allergy Rhinol. 2019 Aug;9(8):850-856.
- 9. Olson MD, Barrera JE. A comparison of an absorbable nasal implant versus functional rhinoplasty for nasal obstruction. Am J Otolaryngol. 2021;42(6):103118.
- American Academy of Otolaryngology—Head and Neck Surgery. Position Statement: Nasal Valve Repair 2023. Available from: https://www.entnet.org/resource/positionstatement-nasal-valve-repair/
- 11. American Rhinologic Society. ARS Position Statement: Bioabsorbable Nasal Implants 2022. Available from: https://www.american-rhinologic.org/index.php?option=com\_ content&view=article&id=477:bioabsorbable-nasal-implants&catid=26:positionstatements&Itemid=197
- 12. CMS' Proposed FY 2025 Inpatient Prospective Payment System: FY 2025 IPPS Proposed Rule Home Page | CMS

### ENT

#### CPT Copyright 2023 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.

The information presented is for illustrative purposes only and is not intended to provide coverage, coding, payment, treatment, or legal advice. It is not intended to guarantee, increase or maximize reimbursement by any payor. Laws, regulations and policies concerning reimbursement are complex, subject to change and updated regularly. Codes should be selected based upon the diagnosis and treatment of individual patients. Stryker ENT does not warrant, promise, guarantee, or payment for treatment using the Stryker products or that any payment received will cover providers' costs. Stryker ENT is not responsible for any action providers are responsible for compliance with Medicare and other payor rules and requirements and other providers are responsible for compliance with Medicare and other payor rules and requirements, confirm the accuracy of their coding or billing practices with their reimbursement advisors and applicable payors and use independent clinical judgment to select obset that most appropriate ly describe the services furnished to a patient. It is the provider's responsibility to determine and document that the services provider are medically necessary and that the site of service is appropriate.

This information is intended solely for the use of healthcare professionals. A healthcare professional must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. We do not dispense medical advice and recommend that healthcare professionals be trained in the use of any particular product before using the product. The information presented is intended to demonstrate the breadth of Stryker product offerings. A healthcare professional must always rely on his or her own professional clinical in all markets because product offerings. A healthcare professional must always refer to the package insert, product label and/or instructions for use. Products may not be available in all markets because product availability of Stryker's products in your area. Stryker or its affiliated entities own, use, or have applied for the following trademarks or service marks: LATERA and Stryker. All other trademarks are trademarks or other intellectual property rights concerning that name or logo.

ENT-LATSYS-REIM-1105924\_REV-2 | Copyright © 2024 Stryker

#### ent.stryker.com

3600 Holly Lane North, Suite 40

Email: ENT-reimbursement@stryker.com

Questions? Call: 844 842 4232

Stryker ENT

0 866 620 7615

Plymouth, MN 55447